US Generics Focus Anchen concentrates on the US market with a focus on extended-release and niche generics, making it a prime partner for firms seeking faster entry into the US generics space through proven ANDA and Paragraph IV capabilities.

Paragraph IV Expertise The company emphasizes speed and creativity in filing Paragraph IV certifications, offering potential for early access to patent-litigation strategies and accelerated product launches as a partner or co-developer.

Integrated Capabilities Fully integrated drug development, manufacturing, and sales organization enables end-to-end partnerships with reduced risk and faster transition from development to market.

Extended-Release Focus Specialization in extended-release formulations and niche generics aligns with market demand for complex products, presenting opportunities for co-development, exclusive licenses, or in-licensing from larger players.

Mid-Sized Flexibility With a lean team and a collaborative culture, Anchen offers agility for milestone-driven deals, contract manufacturing partnerships, and selective co-development with larger pharmaceutical firms seeking flexible capacity and faster US-ready products.